Pediatric Adenocarcinoma in Korea: A Multicenter Study
- Author:
Hee-Beom YANG
1
;
Jung-Man NAMGOONG
;
Ki Hoon KIM
;
Dae Yeon KIM
;
Jinyoung PARK
;
Hyun Beak SHIN
;
Joong Kee YOUN
;
Sanghoon LEE
;
Ji Won LEE
;
Sung Eun JUNG
;
Jae Hee CHUNG
;
Yun-Mee CHOE
;
Tae Gil HEO
;
In Geol HO
;
Hyun-Young KIM
Author Information
- Publication Type:Original Article
- From:Cancer Research and Treatment 2020;52(1):117-127
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:Adenocarcinoma is an extremely rare malignancy in the pediatric population. Research regarding pediatric adenocarcinoma is very rare in Korea. This study aimed to investigate the clinical features of pediatric adenocarcinomas of various primary organ sites in Korea.
Materials and Methods:Pediatric patients under 18 years, diagnosed with adenocarcinoma of various sites between January 1995 and December 2016, were included. We retrospectively reviewed patient and tumor characteristics and calculated survival estimates, reported as 5-year survival rate and 95% confidence interval.
Results:Of 80 patients (median age, 15 years; range, 10 to 17 years), 37 (46.3%) were men, and 24 (30%) had a family history of cancer or underlying disease relevant to malignancy. The cancer locations were the colon and rectum (n=32), ovaries (n=18), stomach (n=15), lung (n=4), small bowel (n=1), and other sites (n=10). Totally, 54.8% patients (42/77) had stage 3 or 4 disease. The median follow-up period was 2.0 years (range, 0 to 20.4). The 5-year overall survival estimate for all patients, and for those with stomach, colorectal, ovarian, and other cancer sites were 57.9%±11.5%, 58.2%±25.7%, 41.5%±18.2%, 87.5%±16.2%, and 64.0%±34.4%, respectively. The 5-year survival rate differed significantly between categories of adenocarcinomas into gastrointestinal (GI) (44.7%) and non-GI adenocarcinomas (78.8%) (p=0.007). The 5-year survival rate also differed significantly according to carcinoembryonic antigen level (69.3% in < 3 ng/mL, 23.8% in > 3 ng/mL; p < 0.001).
Conclusion:In pediatric patients, adenocarcinomas arise from various organs and are often diagnosed at advanced stages. Large, prospective studies for their accurate clinical characteristics and prognostic factors are needed.
